Korea Investment CORP Sells 17,567 Shares of QIAGEN N.V. $QGEN

Key Points

• Korea Investment CORP reduced its stake in QIAGEN N.V. by 18.6%, selling 17,567 shares, and now holds 76,786 shares valued at approximately $3,042,000.
• Several large investors, including Deutsche Bank AG, have significantly increased their positions in QIAGEN, contributing to institutional investors owning 70% of the company's stock.
• QIAGEN recently announced earnings per share of $0.60, meeting analysts' expectations, with revenues of $533.54 million, marking a 7.7% year-over-year increase.

Korea Investment CORP lowered its stake in QIAGEN N.V. (NYSE:QGEN - Free Report) by 18.6% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 76,786 shares of the company's stock after selling 17,567 shares during the quarter. Korea Investment CORP's holdings in QIAGEN were worth $3,042,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also added to or reduced their stakes in QGEN. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in QIAGEN in the 4th quarter worth about $95,746,000. Deutsche Bank AG boosted its stake in QIAGEN by 57.5% in the 1st quarter. Deutsche Bank AG now owns 4,491,131 shares of the company's stock worth $180,319,000 after purchasing an additional 1,639,621 shares during the period. Nuveen LLC bought a new position in QIAGEN in the 1st quarter worth about $44,078,000. Freestone Grove Partners LP bought a new stake in shares of QIAGEN during the 4th quarter valued at about $23,584,000. Finally, Envestnet Asset Management Inc. bought a new stake in shares of QIAGEN during the 1st quarter valued at about $13,463,000. Institutional investors own 70.00% of the company's stock.

QIAGEN Stock Performance

Shares of NYSE QGEN opened at $49.7140 on Friday. The stock has a market cap of $11.05 billion, a price-to-earnings ratio of 29.37, a P/E/G ratio of 2.61 and a beta of 0.64. The company has a current ratio of 1.61, a quick ratio of 1.35 and a debt-to-equity ratio of 0.25. QIAGEN N.V. has a 1-year low of $37.63 and a 1-year high of $51.88. The stock's 50-day moving average is $48.61 and its 200 day moving average is $43.89.

QIAGEN (NYSE:QGEN - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $0.60 earnings per share for the quarter, meeting analysts' consensus estimates of $0.60. The company had revenue of $533.54 million for the quarter, compared to analysts' expectations of $523.97 million. QIAGEN had a return on equity of 14.77% and a net margin of 18.30%.QIAGEN's revenue for the quarter was up 7.7% compared to the same quarter last year. During the same period last year, the firm posted $0.55 EPS. QIAGEN has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. On average, sell-side analysts anticipate that QIAGEN N.V. will post 2.26 EPS for the current fiscal year.

QIAGEN Dividend Announcement

The business also recently declared a dividend, which was paid on Thursday, July 10th. Shareholders of record on Thursday, July 3rd were paid a $0.25 dividend. This represents a yield of 52.0%. The ex-dividend date of this dividend was Wednesday, July 2nd. QIAGEN's payout ratio is 14.79%.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on QGEN. Wall Street Zen downgraded QIAGEN from a "strong-buy" rating to a "buy" rating in a research report on Monday, August 11th. Barclays began coverage on QIAGEN in a research report on Tuesday, June 24th. They set an "overweight" rating and a $55.00 price target for the company. Cowen reiterated a "hold" rating on shares of QIAGEN in a research report on Thursday, August 7th. Bank of America lifted their price target on QIAGEN from $50.00 to $53.00 and gave the company a "buy" rating in a research report on Thursday, June 26th. Finally, UBS Group lifted their price target on QIAGEN from $48.00 to $50.00 and gave the company a "neutral" rating in a research report on Thursday, August 7th. Three equities research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the stock. According to MarketBeat, QIAGEN has an average rating of "Hold" and an average price target of $49.69.

QIAGEN Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.

Want to see what other hedge funds are holding QGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for QIAGEN N.V. (NYSE:QGEN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.